肿瘤预防与治疗2026，Vol.39Issue(1)：5-11,7.DOI:10.3969/j.issn.1674-0904.2026.01.002
EGFR exon20ins晚期非小细胞肺癌不同一线治疗模式的疗效分析:一项全国多中心回顾性研究
Efficacy Analysis of Different First-Line Treatment Modalities for Ad-vanced Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Muta-tions:A National Multicenter Retrospective Study
摘要
Abstract
Objective:Advanced non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor exon 20 insertion(EGFR exon20ins)mutations is characterized by low incidence and limited effective treatments.This retrospec-tive study was conducted to compare the efficacy and safety of different first-line regimens in advanced patients with EGFR exon20ins-mutant NSCLC,aiming to optimize treatment strategies.Methods:Patients with advanced lung cancer harboring EGFR exon20ins who received chemotherapy alone,targeted therapy,or chemotherapy plus antiangiogenic therapy were col-lected from multiple centers.Clinical responses were evaluated by observing progression-free survival(PFS),objective re-sponse rate(ORR),and disease control rate.Cox regression analysis was performed to identify factors influencing PFS.Results:Among the 121 enrolled patients,the median PFS in the chemotherapy-alone group was 8.1 months(95%CI:6.0～10.2 months),with an ORR of 26.2%(11/42);in the targeted therapy group,the median PFS was 7.0 months,with an ORR of 29.7%(11/37);and in the chemotherapy combined with anti-angiogenic therapy group,the median PFS was 6.9 months(95%CI:6.0～7.7 months),with an ORR of 35.7%(15/42).Multivariate analysis revealed that re-gional lymph node metastasis was an independent factor affecting median PFS,with patients having regional lymph node me-tastasis showing a shorter median PFS(6.5 vs 7.3 months,P=0.026).Conclusion:For advanced NSCLC patients with EGFRex20ins mutations,first-line treatment options include chemotherapy,chemotherapy combined with anti-angiogenic therapy,and third-generation EGFR tyrosine kinase inhibitors.Chemotherapy combined with anti-angiogenic therapy may lead to a deeper tumor response.Furthermore,regional lymph node metastasis serves as a correlative factor for PFS.关键词
非小细胞肺癌/表皮生长因子受体/疗效/影响因素Key words
Non-small cell lung cancer/Epidermal growth factor receptor(EGFR)/Efficacy/Influencing factors分类
医药卫生引用本文复制引用
庞燕,罗崧源,邹俊怡,金波,卓明磊,宋正波,杨镇洲,周进..EGFR exon20ins晚期非小细胞肺癌不同一线治疗模式的疗效分析:一项全国多中心回顾性研究[J].肿瘤预防与治疗,2026,39(1):5-11,7.基金项目
四川省科技厅国际港澳台科技创新合作项目(编号:2025YFHZ0248) （编号:2025YFHZ0248）
CSCO重点项目(编号:Y-2021AST/zd-0119) This study was supported by grants from Science and Technology Department of Sichuan Province(No.2025YFHZ0248)and Chinese Society of Clinical Oncology(No.Y-2021AST/zd-0119). （编号:Y-2021AST/zd-0119）
